Health

Want the New Heart Disease Miracle Drug Entresto? It’s Going to Cost You Big Time

The Aug. 12, 2005 file photo shows the logo of Swiss company Novartis in Basel, Switzerland. Swiss pharmaceutical giant Novartis AG announced a series of multibillion-dollar deals Tuesday, April 22, 2014 with other major pharmaceutical companies that it said would reduce sales but boost profitability, while affecting some 15,000 of its employees globally. (AP Photo/Keystone, Steffen Schmidt)
The Aug. 12, 2005 file photo shows the logo of Swiss company Novartis in Basel, Switzerland. (AP Photo/Keystone, Steffen Schmidt)

(Morning Ticker) – Recently we reported on the FDA’s decision to approve Entresto, a new drug from Novartis that has shown an astonishing 20 percent reduction in mortality and hospitalization rates in patients with heart disease, something that has resulted in an excitement from the medical community. But what may be lost in the shuffle is that it may be out of the price range for a lot of patients who need it, particularly those without health insurance.

That’s because Entresto will cost about $12.50 per day, or about $4,500 per year. For those with good health insurance, that might not be a problem, but for those with only partial coverage or no coverage at all, it may be a luxury they simply can’t afford out of pocket — particularly since they’re likely to be paying out the nose for health expenses related to their condition already.

This hefty price tag is expected to be a huge financial boon for drugmaker Novartis, resulting in jolt in shares upon news of the approval from the FDA. The company is so excited about the prospects of the drug that it has ditched convention in not predicting sales of new medication, and instead projects annual sales of $5 billion for the drug. The company is calling it a “once-in-a-lifetime” discovery that could help heart disease patients around the world — that is, if they can afford it, according to a New York Times report.

READ MORE

Tags
Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, http://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Back to top button

My News Matters to me - Washington Informer Donations

Be a Part of The Washington Informer Legacy

A donation of your choice empowers our journalists to continue the work to better inform, educate and empower you through technology and resources that you use.

Click Here Today to Support Black Press and be a part of the Legacy!

Subscribe today for free and be the first to have news and information delivered directly to your inbox.


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, http://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
Close

Adblock Detected

Please consider supporting us by disabling your ad blocker